GENE ONLINE|News &
Opinion
Blog

2022-05-24| Special

Convergence, Communication and Commercialization, The Cornerstones In Emerging Regulatory Trends

by Arvind C. Shekhar
Share To
photo credit to ASCGT

At the recently concluded 25th annual meeting of the American Society for Gene and Cell Therapy (ASGCT), Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration and Dr. Ana Hidalgo-Simon, Head of Advanced Therapies, European Medicines Agency took part in a Fireside chat titled “State of the Field: Emerging Regulatory Trends”. The session was aimed at creating greater awareness about how the two main regulatory agencies (USFDA and EMA) are gearing to regulate the field of cell and gene therapy. In the freewheeling conversation the speakers shared their insights on various aspects ranging from importance of public-private partnerships, lessons learned from COVID-19 to the role of innovative trial design and primary biomarkers in accelerated development of gene therapies. 

 

Role of Public-Private Partnerships In Cell And Gene Therapies

 

GO Prime with only $1.49 now

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top